Skip to main content
. Author manuscript; available in PMC: 2007 Dec 12.
Published in final edited form as: J Immunother. 2007;30(8):825–830. doi: 10.1097/CJI.0b013e318156e47e

TABLE 3.

Objective Tumor Regressions With Ipilimumab

No. Patients Doses of Ipilimumab Response Duration
Cohort A 21
 PR 1 5 18 mo
 CR 0
Cohort B
 Previous IL2 26
  PR 2 4, 4 7, 8 mo
  CR 0
 No previous IL2 14
  PR 3 3, 6, 4 12, 17, 21 mo
  CR 0

CR indicates complete response; PR partial response.